

## Technology Appraisal Committee C Interests Register

### Topic Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]

Publication Date: 06/09/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	Michael has provided consultancy advice to Sanofi in an unrelated disease area (COPD).	09.03.2023	N/A	It was agreed that his declaration would not prevent Michael from participating in discussions on this appraisal.